Prostate Cancer news from FierceBiotech
News
ALSO NOTED: Acorda shares soar; Lexicon wins fast track; NIH grants $533N in research funds; and much more...
> News yesterday that Acorda Therapeutics' experimental MS drug helped patients walk better sent its shares up 27 percent. Read more...
Sonus, OncoGenex to merge
Bothell, WA-based Sonus Pharmaceuticals is merging with Canada's OncoGenex Technologies and will operate under the name OncoGenex Pharmaceuticals. OncoGenex's CEO Scott Cormack will head up the new Read more...
Merck's osteoporosis drug performs in Phase II
Merck's experimental osteoporosis drug odanacatib turned in positive results in a Phase II trial. The drug reduced measures of bone turnover (breakdown and rebuilding of bone) in women with breast Read more...
Pfizer rumored to be eyeing MediGene buyout
Rumors are swirling that Pfizer is looking to take over the German biotech Read more...
Novacea cuts staff after partner dumps collaboration
A month after Schering-Plough pulled the plug on its collaboration with Novacea for a new prostate cancer therapy--Read more...
Optimistic Dendreon revs up second program
Dendreon is making bullish noises about its development efforts. The CMO of the Seattle biotech says that Provenge will deliver positive new data to the FDA on the delayed cancer therapy Provenge Read more...
ALSO NOTED: Targeted Genetics buys Sirna's share of program; Indevus in $21M licensing deal;Atrium Innovations sells division;
> Targeted Genetics has bought out Sirna's share of a Huntington's disease program three years after the partnership began. The deal follows Merck's buyout of Sirna at the end of last year. Read more...
Cell Genesys scores $320M blockbuster deal
Japan's Takeda Pharmaceutical will pay Cell Genesys $50 million upfront and up to $270 million more for hitting Read more...
Oxford BioMedica benefits from TroVax results
Oxford BioMedica shares were boosted by the news that its first mid-stage trial of Read more...
QLT stock rockets as acne drug is cleared for takeoff
Shares of QLT rocketed up 55 percent in a tense market yesterday after the biotech finished a lengthy task in persuading the FDA that a blood test should not be required before doctors prescribe its Read more...
Get more Prostate Cancer coverage at:
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends